Please assess the completion status of the following clinical trial:

Trial Title: RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Binet stage A CLL~* 2 or more risk factors:~* Unmutated IgVH locus (≥98% homology to germline sequence)~* CD38 expression (\>7%)~* Deletion of chromosome 11q22 (\>20% by FISH)~* Deletion of chromosome 17p13 (\>10% by FISH)~* Over 18 years old~* Capable to provide written informed consent~* ECOG performance status \< 2~* Life expectancy \> 2 years~* Must agree to not share lenalidomide with someone else~* Must agree not to donate blood whilst taking the study drug and for one week after discontinuation of treatment.~* Female subjects of childbearing potential and all male subjects must agree to comply with the stipulations of the pregnancy prevention plan.~Exclusion Criteria:~* Current or recent (within the last 1 month) participation in another clinical trial investigating the action of an investigational medicinal product for the treatment of CLL~* Pregnant or lactating~* Known positivity for human immunodeficiency virus (HIV) types 1 or 2~* Prior history of malignancies, other than CLL, unless the subject was treated with curative intent and has been free of the disease for ≥3 years. Exceptions include the following:~* Basal cell carcinoma of the skin~* Squamous cell carcinoma of the skin~* Carcinoma in situ of the cervix~* Carcinoma in situ of the breast~* Significantly abnormal renal or hepatic function (creatinine clearance \< 60ml/min, serum aspartate aminotransferase (AST) \> 3 x upper limit of normal (ULN), serum bilirubin \> 34μmol/l)~* Laboratory tumour lysis syndrome according to the Cairo-Bishop classification. Subjects may be enrolled when these abnormalities have been corrected.~* Peripheral neuropathy (grade ≥ 2)~* Previous treatment for CLL~* Previous treatment with Thalidomide or immunomodulatory derivative drugs (including Lenalidomide)~* Treatment with corticosteroids (for CLL or other indications) \< 28 days from study entry~* Evidence of Richter's transformation~* Unsupported absolute neutrophil count \< 1x109/l or platelet count \< 50x10\*9/l not due to CLL~* Active autoimmune haemolytic anaemia or thrombocytopenia~* Any other medical or psychological condition that in the view of the investigator would be likely to impact compliance with the protocol or interfere with trial treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide for early stage poor prognosis CLL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).